Lilly

Dale M. Edgar, Ph.D. has been appointed executive director and chief scientific leader of Eli Lilly and Co.’s discovery sleep research program. Dr. Edgar has more than 25 years of experience in the field of sleep research. He will report to David Bredt, M.D., vice president of integrated biology.

“We are delighted that Dale has decided to bring his considerable expertise to Lilly,” said Dr. Bredt. “He brings a wealth of experience in sleep research as well as innovative insights into preclinical and clinical drug discovery. We look forward to having him join the team here at Lilly, and to adding renewed emphasis to our sleep disorder research program.”

Dr. Edgar was formerly chief science and technology officer at Hypnion, Inc., a Lexington, MA-based biopharmaceutical company focused on treatments for sleep disorders. He co-founded Hypnion with three other sleep and biological rhythms experts in 2000; Lilly subsequently acquired Hypnion in January of this year. Prior to founding Hypnion, he was Associate Professor of Psychiatry & Behavioral Sciences at Stanford University, and faculty investigator at the Stanford University Sleep Disorders Research Center in California.